Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Claridge


V.TLT

RE:So far, there's no delays in the Ph. 2b

Given the meticulous planning that this company has accustomed us to, do you...

May 30, 2019

V.TLT

Roche could be a perfect suitor looking for an alternative

Roche fits the profile of that perfect suitor that could be looking for an...

May 30, 2019

V.TLT

So far, there's no delays in the Ph. 2b

It's legitimate to ask some questions.  But at one point, some...

May 30, 2019

V.TLT

RE:RE:RE:warrants

JMM1228 ... Great post.   We indeed have so special grumblers here...

May 30, 2019

V.TLT

RE:FDA Oncology Center of Excellence Real-Time Oncology Review

Sounds like our NMIBC Ph. 2b could qualify for that pilot, for our US sites...

May 30, 2019

V.TLT

FDA Oncology Center of Excellence Real-Time Oncology Review

Interesting ones ... Pfizer shifts focus to rural china...

May 30, 2019

V.TLT

Keytruda ...

That will be interesting to displace Merck's blockbuster...

May 29, 2019

V.TLT

RE:RE:RE:RE:1,000 trials studying KEYTRUDA

Still doubt that valuation won't spike on more additional clinical data...

May 29, 2019

V.TLT

RE:RE:1,000 trials studying KEYTRUDA

Eoganacht ...  Good post.  And we have some armchair quaterbacks...

May 29, 2019

V.TLT

Merck's oncology program: 140 abstracts @ASCO 2019

New research from the company’s broad oncology clinical development program...

May 29, 2019

V.TLT

1,000 trials studying KEYTRUDA

"Merck has the industrys largest immuno-oncology clinical research...

May 29, 2019

V.TLT

Keytruda dominance will force competitors to alternatives

The more dominant Merck will be with its Keytruda, the faster one competitor...

May 29, 2019

V.TLT

RE:Where are we atm?

TLT was able to deliver all this with a mere 64M shares (TSO) (from 80M to...

May 29, 2019

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Travis and Bob Said It Perfect in 1959

Mostly thanks to your wife.  

May 29, 2019

V.TLT

RE:Where are we atm?

Fred ... Great post. ________________ fredgoodwinson - (5/29/2019...

May 29, 2019

V.TLT

New Research from Merck’s Broad Oncology Clinical program

May 15, 2019 - New Research from Merck’s Broad Oncology Clinical...

May 28, 2019

V.TLT

RE:Speaking of the China market ...

This is with numbers like these below that justify why big pharmas didn't...

May 28, 2019

V.TLT

Speaking of the China market ...

Of interest, considering our recent 2 China patents ... China's driving...

May 28, 2019

V.TLT

Putting a price on biotechnology

Dates back (2001), but it gives some guidances ... Published in Nature...

May 28, 2019

V.TLT

How Drug Prices Work

Interesting article ... How Drug Prices Work 5/28/2019 7:00AM ...

May 28, 2019

Featured Company